Investigating the interplay between α-Synuclein and fragile X mental retardation protein in Parkinson’s disease
- Weitere Titel
-
Untersuchung des Zusammenspiels zwischen α-Synuclein und dem Fragile X Mental Retardation Protein bei der Parkinson-Krankheit
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
München, Technische Universität München, Dissertation, 2021
- Ereignis
-
Veröffentlichung
- (wo)
-
München
- (wer)
-
Universitätsbibliothek der TU München
- (wann)
-
2021
- Urheber
- Beteiligte Personen und Organisationen
- URN
-
urn:nbn:de:bvb:91-diss-20210609-1584390-1-0
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:45 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Machleid, Felix
- Höglinger, Günter
- Maegdefessel, Lars
- Universitätsbibliothek der TU München
Entstanden
- 2021
Ähnliche Objekte (12)
Models of α-synuclein aggregation in Parkinson’s disease
Dermal α-synuclein oligomers and aggregates in Parkinson’s disease
Role of Apolipoproteins and α-Synuclein in Parkinson’s Disease
The role of Fragile X Mental Retardation Protein in Parkinson’s disease
Erythrocytic α-Synuclein as a potential biomarker for Parkinson’s disease
Initiation and progression of α-synuclein pathology in Parkinson’s disease
GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson’s Disease
Adenosine A1 receptor ligands bind to α-synuclein: implications for α-synuclein misfolding and α-synucleinopathy in Parkinson’s disease
Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease
Retinal α-synuclein deposits in Parkinson’s disease patients and animal models
Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity
Association of Glial Activation and α-Synuclein Pathology in Parkinson’s Disease
Models of α-synuclein aggregation in Parkinson’s disease
Dermal α-synuclein oligomers and aggregates in Parkinson’s disease
Role of Apolipoproteins and α-Synuclein in Parkinson’s Disease
The role of Fragile X Mental Retardation Protein in Parkinson’s disease
Erythrocytic α-Synuclein as a potential biomarker for Parkinson’s disease
Initiation and progression of α-synuclein pathology in Parkinson’s disease
GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson’s Disease
Adenosine A1 receptor ligands bind to α-synuclein: implications for α-synuclein misfolding and α-synucleinopathy in Parkinson’s disease
Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease
Retinal α-synuclein deposits in Parkinson’s disease patients and animal models
Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity
Association of Glial Activation and α-Synuclein Pathology in Parkinson’s Disease
Models of α-synuclein aggregation in Parkinson’s disease
Dermal α-synuclein oligomers and aggregates in Parkinson’s disease
Role of Apolipoproteins and α-Synuclein in Parkinson’s Disease
The role of Fragile X Mental Retardation Protein in Parkinson’s disease
Erythrocytic α-Synuclein as a potential biomarker for Parkinson’s disease
Initiation and progression of α-synuclein pathology in Parkinson’s disease
GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson’s Disease
Adenosine A1 receptor ligands bind to α-synuclein: implications for α-synuclein misfolding and α-synucleinopathy in Parkinson’s disease
Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease
Retinal α-synuclein deposits in Parkinson’s disease patients and animal models
Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity